A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.
This study has been completed.
Sponsor:
Duramed Research
Information provided by:
Duramed Research
ClinicalTrials.gov Identifier:
NCT00196352
First received: September 12, 2005
Last updated: January 8, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
This study is being conducted to evaluate the safety of ethinyl an extended-regimen oral contraceptive, with ethinyl estradiol supplementation during the usual hormone-free week, for up to an additional three consecutive years.
Condition | Intervention | Phase |
---|---|---|
Contraception |
Drug: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
Official Title: | A Prospective, Multiple Site Study to Evaluate the Safety of an Extended Cycle Combination Oral Contraceptive, Seasonique, Which Utilizes Ethinyl Estradiol During the Pill-free Interval. |
Resource links provided by NLM:
MedlinePlus related topics:
Birth Control
Drug Information available for:
Estradiol
Estradiol cypionate
Levonorgestrel
Estradiol valerate
Estradiol acetate
U.S. FDA Resources
Further study details as provided by Duramed Research:
Primary Outcome Measures:
- Patient and Investigator reports of adverse events [ Time Frame: Duration of Study ] [ Designated as safety issue: Yes ]
Enrollment: | 320 |
Study Start Date: | May 2003 |
Study Completion Date: | November 2006 |
Primary Completion Date: | November 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1 |
Drug: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets
1 tablet daily
Other Name: Seasonique
|
Detailed Description:
This study is being conducted to evaluate the safety of an extended-regimen oral contraceptive, with ethinyl estradiol supplementation during the usual hormone-free week, for up to an additional three consecutive years. This is an extension of the Seasonique Phase 3 clinical trial to evaluate long-term safety. Only patients enrolled in the earlier trial are eligible for participation.
Eligibility
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Participant in the earlier Phase 3 Seasonique clinical trial
Exclusion Criteria:
- Any contraindication to the use of oral contraceptives
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00196352
Locations
United States, Arizona | |
Duramed Investigational Site | |
Tucson, Arizona, United States, 85715 | |
United States, District of Columbia | |
Duramed Investigational Site | |
Washington, District of Columbia, United States, 20006 | |
United States, Nebraska | |
Duramed Investigational Site | |
Lincoln, Nebraska, United States, 68510 | |
United States, New York | |
Duramed Investigational Site | |
Rochester, New York, United States, 14609 | |
United States, North Carolina | |
Duramed Investigational Site | |
Charlotte, North Carolina, United States, 28209 | |
Duramed Investigational Site | |
Winston-Salem, North Carolina, United States, 27103 | |
United States, Ohio | |
Duramed Investigational Site | |
Columbus, Ohio, United States, 43213 | |
United States, Oklahoma | |
Duramed Investigational Site | |
Oklahoma City, Oklahoma, United States, 73112 | |
United States, Tennessee | |
Duramed Investigational Site | |
Nashville, Tennessee, United States, 37203 | |
United States, Virginia | |
Duramed Investigational Site | |
Arlington, Virginia, United States, 22203 | |
Duramed Investigational Site | |
Norfolk, Virginia, United States, 23507 |
Sponsors and Collaborators
Duramed Research
Investigators
Study Chair: | Duramed Protocol Chair | Duramed Research, Inc. |
More Information
No publications provided
Keywords provided by Duramed Research:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
No publications provided
Responsible Party: | Duramed Protocol Chair, Duramed Research, Inc. |
ClinicalTrials.gov Identifier: | NCT00196352 History of Changes |
Other Study ID Numbers: | PSE-304 |
Study First Received: | September 12, 2005 |
Last Updated: | January 8, 2010 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by Duramed Research:
oral contraceptives birth control ethinyl estradiol pregnancy prevention |
Additional relevant MeSH terms:
Contraceptive Agents Levonorgestrel Ethinyl estradiol, levonorgestrel drug combination Contraceptives, Oral Ethinyl Estradiol Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions |
Therapeutic Uses Contraceptive Agents, Female Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Contraceptives, Oral, Synthetic Contraceptives, Oral, Combined |
ClinicalTrials.gov processed this record on October 16, 2012